Literature DB >> 19727816

Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status.

Alexander Hoellein1, Thomas Decker, Christian Bogner, Madlen Oelsner, Stefanie Hauswald, Christian Peschel, Ulrich Keller, Thomas Licht.   

Abstract

PURPOSE: To assess whether the poor prognosis of ZAP70-positive B-cell chronic lymphocytic leukemia (CLL) is associated with the overexpression of ABC transporter genes that are responsible for pleiotropic drug resistance.
MATERIALS AND METHODS: The transcript level of ten drug transporters was analyzed using semiquantitative and quantitative RT-PCR in control hematopoietic cells, in 41 CLL patient samples and in 5 lymphoma cell lines. ZAP70 status was determined by immunoblotting.
RESULTS: Of all analyzed transporters, MDR1, MDR2, MRP1, MRP4, MRP5, and MRP7 were expressed at a significantly higher level in B lymphocytes when compared with other hematopoietic cells in peripheral blood. A subgroup of 41 CLL patient samples showed similar or higher expression of these genes than control B cells, and CLL cells exhibited high expression when compared with multiple lymphoma cell lines. No significant correlation between ZAP70 expression and ABC transporter expression was observed.
CONCLUSION: The ZAP70 status is independent of the multidrug resistance phenotype in CLL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19727816     DOI: 10.1007/s00432-009-0670-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.

Authors:  Míriam Molina-Arcas; Beatriz Bellosillo; F Javier Casado; Emili Montserrat; Joan Gil; Dolors Colomer; Marçal Pastor-Anglada
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

Review 2.  Update on risk-stratified management for chronic lymphocytic leukemia.

Authors:  Clive S Zent; Timothy G Call; William J Hogan; Tait D Shanafelt; Neil E Kay
Journal:  Leuk Lymphoma       Date:  2006-09

3.  Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.

Authors:  A G Bosanquet; S A Johnson; S M Richards
Journal:  Br J Haematol       Date:  1999-07       Impact factor: 6.998

4.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.

Authors:  P M Chaudhary; I B Roninson
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

5.  Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.

Authors:  Maria Ilaria Del Principe; Giovanni Del Poeta; Francesco Buccisano; Luca Maurillo; Adriano Venditti; Antonella Zucchetto; Rita Marini; Pasquale Niscola; Maria Antonietta Irno Consalvo; Carla Mazzone; Licia Ottaviani; Paola Panetta; Antonio Bruno; Riccardo Bomben; Giovanna Suppo; Massimo Degan; Valter Gattei; Paolo de Fabritiis; Maria Cantonetti; Francesco Lo Coco; Domenico Del Principe; Sergio Amadori
Journal:  Blood       Date:  2006-04-06       Impact factor: 22.113

6.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

7.  Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation.

Authors:  K Nooter; P Sonneveld; A Janssen; R Oostrum; T Boersma; H Herweijer; D Valerio; A Hagemeijer; F Baas
Journal:  Int J Cancer       Date:  1990-04-15       Impact factor: 7.396

8.  Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.

Authors:  H Herweijer; P Sonneveld; F Baas; K Nooter
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

9.  Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.

Authors:  Thomas Decker; Madlene Oelsner; Robert J Kreitman; Giuliana Salvatore; Qing-cheng Wang; Ira Pastan; Christian Peschel; Thomas Licht
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  3 in total

1.  Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients.

Authors:  Farzad Maroofi; Sabrieh Amini; Daem Roshani; Bayazid Ghaderi; Mohammad Abdi
Journal:  Tumour Biol       Date:  2015-01-15

2.  Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.

Authors:  Amit K Mittal; Nagendra K Chaturvedi; Karan J Rai; Christine E Gilling-Cutucache; Tara M Nordgren; Margaret Moragues; Runqing Lu; Rene Opavsky; Greg R Bociek; Dennis D Weisenburger; Javeed Iqbal; Shantaram S Joshi
Journal:  Mol Med       Date:  2014-07-15       Impact factor: 6.354

Review 3.  Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis.

Authors:  Philip Savage
Journal:  BMC Cancer       Date:  2016-11-21       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.